ONCOSIGNATURE Trademark

Trademark Overview


On Thursday, August 3, 2023, a trademark application was filed for ONCOSIGNATURE with the United States Patent and Trademark Office. The USPTO has given the ONCOSIGNATURE trademark a serial number of 98115652. The federal status of this trademark filing is OPPOSITION PENDING as of Friday, November 1, 2024. This trademark is owned by Acrivon Therapeutics, Inc.. The ONCOSIGNATURE trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical and medical preparations for the prediction of drug treatment efficacy; pharmaceutical and medical preparations for prognosis related to cancer; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing, specifically in oncology and premalignant disorders and benign tumors; reagents for medical use, namely, for medical diagnosis, drug-tailored efficacy predication and analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use in the field of oncology in the form of a clinical biomarker signature assay on biopsy or other patient sample material for measuring biomarkers reflective of disease-driving processes that the drug inhibits or does not inhibit to predict treatment efficacy within oncology; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; companion diagnostic biomarker reagents for medical purposes

Medical services; medical testing for diagnosis or treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing medical information, consultancy and advisory services; individual medical counseling services provided to patients; providing a website featuring information in the fields of oncology and precision medicine; providing medical information to medical professionals in the form of reports in the fields of oncology and precision medicine
oncosignature

General Information


Serial Number98115652
Word MarkONCOSIGNATURE
Filing DateThursday, August 3, 2023
Status774 - OPPOSITION PENDING
Status DateFriday, November 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements


Goods and ServicesPharmaceutical and medical preparations for the prediction of drug treatment efficacy; pharmaceutical and medical preparations for prognosis related to cancer; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing, specifically in oncology and premalignant disorders and benign tumors; reagents for medical use, namely, for medical diagnosis, drug-tailored efficacy predication and analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use in the field of oncology in the form of a clinical biomarker signature assay on biopsy or other patient sample material for measuring biomarkers reflective of disease-driving processes that the drug inhibits or does not inhibit to predict treatment efficacy within oncology; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; companion diagnostic biomarker reagents for medical purposes
Pseudo MarkON CO SIGNATURE
Goods and ServicesMedical services; medical testing for diagnosis or treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing medical information, consultancy and advisory services; individual medical counseling services provided to patients; providing a website featuring information in the fields of oncology and precision medicine; providing medical information to medical professionals in the form of reports in the fields of oncology and precision medicine

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 1, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 1, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAcrivon Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Party NameAcrivon Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Trademark Events


Event DateEvent Description
Monday, August 7, 2023NEW APPLICATION ENTERED
Friday, September 1, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 26, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, October 26, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 26, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 26, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 26, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 4, 2024ASSIGNED TO EXAMINER
Thursday, April 4, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 5, 2024EXTENSION OF TIME TO OPPOSE RECEIVED
Friday, November 1, 2024OPPOSITION INSTITUTED NO. 999999
Sunday, November 3, 2024EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED